1. Home
  2. STTK vs ANPA Comparison

STTK vs ANPA Comparison

Compare STTK & ANPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$4.01

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

ANPA

Rich Sparkle Holdings Limited Ordinary Shares

N/A

Current Price

$69.89

Market Cap

300.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
ANPA
Founded
2016
2016
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
300.0M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
STTK
ANPA
Price
$4.01
$69.89
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$6.20
N/A
AVG Volume (30 Days)
893.1K
151.5K
Earning Date
11-06-2025
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$1,000,000.00
$5,832,684.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$2.80
52 Week High
$4.89
$108.68

Technical Indicators

Market Signals
Indicator
STTK
ANPA
Relative Strength Index (RSI) 49.25 53.82
Support Level $3.92 $63.24
Resistance Level $4.46 $83.00
Average True Range (ATR) 0.35 28.77
MACD -0.12 -2.26
Stochastic Oscillator 20.64 23.42

Price Performance

Historical Comparison
STTK
ANPA

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.

Share on Social Networks: